Guggenheim Reiterates Buy Rating on Abivax, Keeps $175 Price Target
Guggenheim reiterated its Buy rating on Abivax and a $175 price target. The target implies 124.5% upside from the Oct. 19 close of $77.95.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BTIG reiterates Buy rating on Abivax, $175 target
BTIG reiterated a Buy rating on Abivax and set a $175.00 price target, implying 93.1% upside from the Sep 21 close of $90.65.
Abivax Rating Reiterated
Citizens reiterates Abivax stock rating due to confidence in maintenance trial. This move may impact Abivax's stock performance.